The law targeting data mining in Vermont, along with laws in New Hampshire and Maine, would have forced drug companies to significantly change the way they market drugs to physicians had the Supreme Court allowed them to stand in the case of Sorrell, Attorney General of Vermont, et al. vs. IMS Health Inc., et al.
The Supreme Court has struck down a law in Vermont designed to encourage generic drug usage by limiting the sharing of information about what branded drugs doctors prescribe, so that drug companies could use it when crafting sales pitches, according to published reports.
The latest drug trend report from pharmacy benefit manager Express Scripts estimated that if patients using maintenance medications used cheaper therapies when possible, adhered to their medication therapies and used home delivery, it could eliminate $403 billion in pharmacy waste every year.
In its “2010 Drug Trend Report,” Express Scripts attributed much pharmacy-related waste to patients failing to follow three simple guidelines: Take medications as prescribed, take drugs that maximize clinical benefit for the lowest price and use the safest and cheapest delivery channel.
The Healthcare Distribution Management Association on Monday awarded eight leading pharmaceutical and consumer product manufacturers through the presentation of its annual Distribution Industry Awards for Notable Achievements in health care.
The White House on Friday held a roundtable discussion with approximately two dozen leaders across the public safety, healthcare and technology sectors to address how health information technology can help limit prescription drug abuse, the National Community Pharmacists Association noted in a release on Monday.
As part of a series on prescription drugs in America, CNN’s “American Morning” program on Wednesday hosted Safeguard My Meds spokesman and National Community Pharmacists Association executive committee member Keith Hodges to discuss pharmacy robberies and prescription drug abuse in a segment called “Pharmacies as Targets.”
Drug maker Johnson & Johnson plans to file for regulatory approval for 11 new drugs between 2011 and 2015, the company said Thursday in relation to a meeting between J&J’s executive committee and investors.